Threshold Pharmaceuticals News

The Fresh Market, Inc. : Cowen previewed Q1 results for The Fresh Market which is scheduled to report May 30th and expects continued comp momentum, accelerating unit growth, and sees benefits from moderating food inflation trends.

Cowen said Threshold Pharmaceuticals remains undervalued in relation the potential of it's TH-302 drug for pancreatic cancer.

There are two companies making headlines these days on their trials and drugs targeting and related to Leukemia patients.

Without question, Threshold Pharmaceuticals, Inc. is on the cusp of becoming a blockbuster stock for those of you following the new developments, their pipeline, orphan drug status, EU approval, and discovery into Hypoxia and how it relates to cancer .

So far, 2012 has been the best year for the Biotechnology and Drugs industry. So many stocks have surged in the last four months based on clinical trial results, U.S. Food and Drug Administration approval, FDA Advisory Committee's recommendation, European commission approval, recommendation from independent committees, partnership with big ... (more)